Celltrion has secured U.S. FDA acknowledgment of an amended Phase 3 trial protocol for CT‑P51, its biosimilar to Merck’s immuno-oncology drug Keytruda, in previously untreated metastatic non-squamous non-small cell lung cancer

CT-P51 (pembrolizumab biosimilar) - Celltrion

Sep 7, 2026